The Effect Of Mrd Monitoring By Multiparameter Flow Cytometry Before Pretreatment On The Prognosis In AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

ObjectiveTo analyze the effect of multiparameter flow cytometry(MFC)monitoring of acute myeloid leukemia(AML)pretreatment of bone marrow minimal residual disease(MRD)on the prognosis of allogeneic hematopoietic stem cell transplantation(allo-HSCT),and to investigate the value of MRD monitoring by MFC before allo-HSCT to assess the prognosis in AML.MethodsA retrospective analysis of 58 patients with AML who underwent allo-HSCT in our center from April 2014 to December 2018.Before pretreatment,bone marrow specimens were detected by MRD with ten-color flow cytometry,and according to the MRD,patients were divided into the group of MRD <1% and the goup of MRD> 1%.Results(1)Of the 58 patients with AML,39 cases had MRD <1% and 19 cases had MRD>1%.(2)Of the 58 cases,38 cases survived disease-free and the total disease-free survival rate was 65.5%.Among the 39 cases with MRD<1%,29 cases survived disease-free,the disease-free survival rate was 74.4%;5 cases had recurrence,the recurrence rate was 12.8%;5cases were non-recurrent death,and the non-recurrence mortality rate was12.8%.MRD>1% had 19 cases,of which 9 cases were survived disease-free,the disease-free survival rate was 47.4%;7 cases had recurrence,the recurrence rate was 36.8%;3 cases were non-recurrent death,and the non-recurrence mortality rate was 15.8%.(3)The average overall survival(OS)of MRD<1% group was 38.99 months,and the average OS of MRD>1% group was 26.16 months(P=0.127).(4)The average disease-free survival(DFS)of MRD<1% group was 37.81 months,and the average DFS of MRD>1% group was 22.80 months(P=0.049).ConclusionAllogeneic hematopoietic stem cell transplantation is an effective treatment for AML patients to survive disease-free.The MRD monitored by MFC before allo-HSCT is important for the prognosis of AML patients.